---
title: "Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287906180.md"
description: "Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News"
datetime: "2026-05-28T03:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287906180.md)
  - [en](https://longbridge.com/en/news/287906180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287906180.md)
generator: "portal-rs"
---

# Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)

## Related News & Research

- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)
- [Zenas Biopharma director Christy J. Oliger files initial beneficial ownership statement](https://longbridge.com/en/news/297823217.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says](https://longbridge.com/en/news/297819704.md)
- [Zenas BioPharma highlights FDA review acceptance for obexelimab IgG4-RD filing in corporate presentation](https://longbridge.com/en/news/297520266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**